ASH 2025: CLY-124, a first-in-class DCN1 inhibitor partially suppresses CUL3 neddylation and induces fetal hemoglobin is a new potential treatment for sickle cell disease
Cellarity Presents on Cell State-Correcting Pipeline Programs for Sickle Cell Disease and Myelofibrosis at 2025 American Society of Hematology Annual Meeting
